Ozempic and Personality
DESCRIPTION:
Weight-loss injections & mental health: How do weight-loss injections such as semaglutide affect personality? Find out more about possible side effects, suicidal thoughts and more.
Ozempic and Co.: Weight-loss injections, Wegovy and side effects of GLP-1 receptor agonists
In spring 2026, there are increasing reports of patients who, whilst taking the active ingredient semaglutide, are not only losing weight but also experiencing emotional numbness. At the same time, large registry studies show significantly lower rates of depression and anxiety among those taking the drug. This text examines the paradox from neurobiological, clinical and cultural-critical perspectives and takes the common side effects of weight-loss injections seriously, without succumbing to the ‘miracle cure’ narrative.
What does the term ‘Ozempic personality’ mean?
“Ozempic personality” is not a diagnosis but a description that went viral in patient forums, in the “Washington Post,” and on KTLA in early 2026. Semaglutide preparations such as Ozempic induce a peculiar flatness in some users, which they observe in themselves: less desire for food, but also less desire for music, sex, hobbies and conversation. Doctors and patients describe the experience as “dull” or “detached”. It is important to draw a distinction: this is not a classic depressive episode involving guilt, hopelessness or suicidal thoughts, but rather a diminished sense of desire and a reduced capacity for emotional resonance. The term refers to a cluster of symptoms. It belongs in clinical observation, not in the ICD code.
Wegovy, Ozempic and Saxenda: How do these weight-loss injections differ?
Behind the brand names lie related but not identical substances. Ozempic and Wegovy both contain semaglutide from the Danish manufacturer Novo Nordisk. The former is approved as a diabetes medication for the treatment of type 2 diabetes, the latter for the treatment of overweight and obesity. Saxenda contains the older liraglutide and is also approved for obesity therapy, with daily rather than weekly administration. Mounjaro, which contains tirzepatide, also binds to the GIP receptor and is currently considered the most potent representative of this class of substances. What they all have in common is their effect on the hormone GLP-1: they slow gastric emptying, enhance the feeling of satiety and influence the reward system.
For which indication is each drug approved, and what does ‘off-label’ mean?
The formal indication for the drug is the treatment of type 2 diabetes in adults when dietary changes and exercise are insufficient. The sister product is indicated for the treatment of obesity from a body mass index of 30 or from a BMI of 27 with comorbidities such as high blood pressure, cardiovascular risks or cardiovascular disease. Saxenda has a similar indication. In practice, however, semaglutide preparations are frequently prescribed off-label, i.e. outside the approved indication, for example, for people with a normal BMI who wish to lose weight for aesthetic reasons. This is legally permissible, but clinically problematic, because safety data were primarily collected for the target group of overweight patients, not for slim users with cosmetic goals.
What are the most common side effects of the drug?
Common side effects include stomach discomfort, diarrhoea, constipation, abdominal pain and heartburn – in other words, the full range of gastrointestinal reactions attributable to delayed gastric emptying. Around one in five patients experiences severe nausea during the first month, which usually subsides over time or with a gradual increase in dosage. Less common, but serious, side effects include inflammation of the pancreas (pancreatitis), inflammation of the bile ducts, low blood pressure, dizziness in people with diabetes on combination insulin therapy, and isolated reports of joint inflammation. The EMA lists these effects in the current product information.
Does the medication increase the risk of suicidal thoughts and self-harm?
The data on this is particularly confusing. An analysis referenced by Mercola.com in May 2026 reports a 45 per cent increased risk of suicidal thoughts compared to other antidiabetic drugs. The headline is circulating on alternative health portals, but its methodology is questionable because it is based on spontaneous FAERS reporting data, which is distorted by reporting bias. The EMA, as the European Medicines Agency and thus the competent medicines authority, has been unable to find a causal link between GLP-1 drugs and self-harm or suicidal acts in several evaluations. (However, the biased handling of reporting data by the FDA and the EMA has also been repeatedly demonstrated.)
On the contrary, a cohort study published in the journal Lancet Psychiatry in 2026 reports a lower risk of self-harm among those taking semaglutide. Clinically, the following remains true: in cases of pre-existing depression or suicidal tendencies, caution and close monitoring are required, but robust data do not support scaremongering.
Nausea, vomiting and delayed gastric emptying: how common?
The active ingredient slows gastric emptying by an average of 30 to 70 per cent in the first few weeks of use. This explains the increased incidence of gastrointestinal symptoms. Studies show severe stomach complaints in 20 to 40 per cent of those treated at therapeutic doses, significantly higher than in the placebo group. Vomiting occurs in around 9 to 16 per cent of cases. These effects are generally dose-dependent and diminish over the course of treatment; they are less of a safety issue than a comfort issue and require careful dose titration. It is noteworthy that the gastrointestinal symptoms are also part of the mechanism of action: those who feel nauseous eat less.
What does the 2026 Lancet study say about weight loss and mental health?
The Swedish-Finnish-Australian cohort study published in *The Lancet Psychiatry* in 2026 followed nearly 100,000 people from Swedish registers between 2009 and 2022, of whom over 20,000 were on GLP-1 therapy. During periods of treatment, the risk of worsening psychiatric outcomes was reduced by 42 per cent compared to periods without treatment; the risk of depression was reduced by 44 per cent, the risk of anxiety disorders by 38 per cent, and the risk of substance use disorders by 47 per cent. The authors emphasise that these are observed associations, not causal evidence; a randomised trial is still pending. But the magnitude is substantial, the effect is consistent across multiple endpoints, and at first glance, it directly contradicts what users describe as an ‘Ozempic personality’.
What mechanism does neurobiology suggest lies behind weight loss and anhedonia?
The hormone GLP-1 binds to receptors found not only in the hypothalamus and pancreas, but also in the brainstem, the prefrontal cortex and, crucially, in the (mesolimbic) dopamine system. Studies on the nucleus accumbens show that chronic GLP-1 activation dampens phasic dopamine bursts – precisely those brief spikes in signalling that the brain uses to mark rewards. This reduces not only the appeal of high-calorie food but also, potentially, that of any rewarding experience. The tonic dopamine baseline – the quiet background noise that underpins motivation and interest – is also affected. Biochemically, the reward system does not distinguish between pizza, pornography, pop songs and conversations with a partner; if you turn down the volume on a master control, everything else becomes quieter too. This explains the flip side of the effect: significant weight loss accompanied by a reduction in addictive behaviour, desire and interest.
How can the paradox between the study findings and self-reports be resolved?
Three explanations complement one another. Firstly, the study measures clinical diagnoses, hospital admissions and sick leave – in other words, severity. Emotional numbness does not result in a diagnosis, but rather a creeping erosion of one’s experience, which remains invisible within the healthcare system.
Secondly, those suffering from obesity are disproportionately likely to also suffer from depression and anxiety, both of which are closely linked to stigma, pain, social exclusion, and inflammatory processes. Weight loss in this group massively reduces these burdens; the positive effect overshadows the smaller subgroup in which the dopamine system is significantly dampened.
Thirdly, depending on the starting point, this same suppression can have a healing or pathological effect. Those suffering from compulsive eating, addictive urges or constant inner cravings experience the suppression as a liberation. Those who are already running low on dopamine – following burnout, with Long Covid, or during the grieving process – are more likely to slip into a state of joylessness.
What are the clinical implications for psychotherapy?
In practical terms, this means that a medical history must explicitly include GLP-1 receptor agonists, not only as a treatment for diabetes, but as substances with psychotropic relevance. Anyone coming to the practice with a loss of drive, loss of interest, loss of sexual desire or ‘emotional exhaustion’ should be asked whether they are using semaglutide, tirzepatide or liraglutide – even outside the approved indication – as grey-market channels for weight-loss injections are common.
In terms of differential diagnosis, it is important to distinguish GLP-1-induced mood changes from endogenous depression, a mood slump in response to rapid changes in body weight, grief over the loss of one’s former identity as ‘the fat one’, and SSRI-induced emotional blunting.
Therapeutic implications: discuss the pace of dose escalation with prescribers; consider breaks; implement parallel behavioural activation strategies; structure rewarding activities; and provide supplementary psychotherapeutic support where appropriate.
What does this mean for addiction medicine and addictive behaviour?
If GLP-1 receptor agonists globally dampen the reward system, the obvious question is: Does this help against addiction? Initial findings are encouraging. The Swedish registry study shows a 47 per cent reduction in the risk of substance use disorders among those undergoing treatment. Animal studies with exendin-4 show reduced dopamine release and reduced addictive behaviour following exposure to amphetamine and cocaine. Clinical reports from the USA document spontaneous reductions in alcohol consumption and nicotine cravings. This is therapeutically attractive, yet ethically delicate. If anhedonia is the lever of addiction therapy, abstinence comes at the cost of a duller life. This is an old debate from methadone and naltrexone research in a new pharmacological guise: we learn to curb desire, and must ask ourselves what remains once that desire is gone.
What does this have to do with dopamine as the ‘happiness hormone’?
This is precisely where a popular scientific misconception comes into play: dopamine is not a happiness hormone, but a ‘wanting’ signal. It marks salience – in other words, ‘you should pay attention to this’ – and it drives approach behaviour.
The actual ‘liking’ – the pleasurable immersion in an experience – is primarily driven by endogenous opioids and the endocannabinoid system.
When semaglutide dampens dopamine signalling, the world loses its appeal. Users often describe it exactly like this: “I can still see the sunset; objectively, I find it beautiful, but it no longer moves me.” This is phenomenologically precise and important for differential diagnosis; it distinguishes GLP-1 anhedonia from classic depression, in which the world also appears grey and hostile.
What do we want?
This is where pharmacology ends and cultural criticism begins. A society that demands self-optimisation, slimness, efficiency and constant availability develops a miracle cure that meets these demands precisely by dampening desire. Less hunger, less addiction, less suicidal tendencies, but also less desire, less grief, and less interest. This is not a cynical pharmaceutical conspiracy, but a logical reflection of what an exhausted late modernity demands of its subjects: to function without feeling. If the solution to the diseases of excess is to want less, then the critical question must at least be asked: have we become subjects who experience our desire as a burden? And what would it mean to lead a life in which one would have to learn once again to want something that is not measurable?
Key findings at a glance
· “Ozempic personality” is a description of emotional flattening under semaglutide; it is not a clinical diagnosis and is not listed in the DSM-5 or ICD-11.
· Users report a reduced desire for food, hobbies, sex and social contact; the experience is described as “dulled”, without classic depressive symptoms such as hopelessness or guilt.
· Common side effects include stomach discomfort, nausea, constipation and diarrhoea; less common are pancreatitis, inflammation of the bile ducts, dizziness, low blood pressure or joint inflammation.
· The suspected mechanism lies in the attenuation of phasic dopamine bursts in the mesolimbic reward system; GLP-1 receptors do not act selectively on food motivation.
· The 2026 Lancet Psychiatry study involving nearly 100,000 people shows a 44 per cent reduction in depression, a 38 per cent reduction in anxiety disorders and a 47 per cent reduction in substance use disorders among those taking the medication.
· The paradox is partly resolved because studies record diagnoses, not subclinical flattening; because obesity-related depression decreases significantly with weight loss; and because the same dopamine attenuation can have a liberating or pathological effect depending on the initial situation.
· The FDA and the EMA have so far found no causal link between the substances and suicidality; the ‘45 per cent headline’ circulating in May 2026 stems from methodologically biased FAERS reporting data. However, the FDA and the EMA’s biased handling of reporting data has also been repeatedly demonstrated.
· By 2026, psychotherapy should explicitly cover the entire class of substances and distinguish them, through differential diagnosis, from endogenous depression, SSRI-induced emotional blunting and identity crises following rapid weight loss.
· From an addiction medicine perspective, the class of substances is promising but ethically ambivalent: it reduces craving through global dopamine suppression, and thus also the craving for non-addictive, life-affirming stimuli.
· Dopamine is a ‘wanting’ signal, not a ‘liking’ signal; the drug reduces attraction, not beauty; this distinction is clinically and biographically crucial.
· Culturally, the drug is a mirror: a society that pushes its subjects towards permanent functioning without feeling receives the drug it demands; the critical question concerns not the substance itself, but the conditions under which it is desired.
Related